Among patients with muscle-invasive urothelial carcinoma (MIUC), the presence of detectable circulating tumor DNA (ctDNA) after surgery may identify those who are likely to benefit from adjuvant immunotherapy with the immune checkpoint inhibitor atezolizumab (Tecentriq). The finding comes from a new analysis of data from the ImVigor010 trial, which had failed to reach its primary